CBD Kills Cancer Cells in the Lab While Sparing Normal Cells
CBD showed selective cytotoxicity against three human cancer cell lines (cervical, breast, and colon) while leaving non-cancerous cells relatively unharmed.
Quick Facts
What This Study Found
CBD at 5-20 micromolar concentrations killed cancer cells through apoptosis with LC50 values of 9.4 (HeLa cervical), 10.3 (MDA-MB-231 breast), and 4.3 (CaCo-2 colon) micromolar at 24 hours. Non-cancerous cell lines (HaCaT skin, HUVEC endothelial) were relatively spared.
Key Numbers
LC50 at 24h: HeLa 9.4 micromolar, MDA-MB-231 10.3 micromolar, CaCo-2 4.3 micromolar. Tested at 5, 10, and 20 micromolar for 24, 48, 72, and 96 hours. Apoptosis confirmed by flow cytometry.
How They Did This
In vitro study treating three human cancer cell lines and two non-cancerous control lines with CBD at multiple concentrations (5, 10, 20 micromolar) across four time points (24-96 hours), using MTT assays, DAPI nuclear staining, and flow cytometry.
Why This Research Matters
The selectivity of CBD for cancer cells over normal cells is a key finding. Many cancer treatments damage healthy tissue, so a compound that preferentially targets cancer cells has obvious therapeutic potential.
The Bigger Picture
CBD anti-cancer research is expanding rapidly. The selectivity seen here adds to growing evidence that cannabinoids interact differently with cancer versus normal cells, potentially through differences in cannabinoid receptor expression.
What This Study Doesn't Tell Us
In vitro results often do not translate to living organisms. CBD concentrations tested may not be achievable in human tumors. No comparison with standard chemotherapy drugs. Cell line experiments are simplified models of complex cancers.
Questions This Raises
- ?Can these CBD concentrations be achieved in human tumors?
- ?Would CBD enhance conventional chemotherapy?
- ?What mechanisms explain the selectivity for cancer cells?
Trust & Context
- Key Stat:
- CBD killed cancer cells at low micromolar doses while sparing normal cells
- Evidence Grade:
- Well-designed in vitro study with appropriate controls, but cell line experiments are far from clinical relevance.
- Study Age:
- 2025 in vitro study adding to the growing CBD-cancer research literature.
- Original Title:
- Targeting Human Cancer Cells with Cannabidiol (CBD): Apoptotic Cytotoxicity in HeLa, MDA-MB-231, and CaCo-2 Lines.
- Published In:
- International journal of molecular sciences, 26(24) (2025)
- Authors:
- Montes-de-Oca-Saucedo, Carlos R, Perales-Martínez, Jonathan E, Arellano-Barrientos, Juan C, Rodríguez-Tovar, Luis E, Nevárez-Garza, Alicia M, Garza-Arredondo, Aimé J, Saucedo-Cárdenas, Odila, Hernández-Vidal, Gustavo, Soto-Domínguez, Adolfo, Castillo-Velázquez, Uziel
- Database ID:
- RTHC-07174
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can CBD treat cancer?
In this lab study, CBD killed cancer cells while leaving normal cells relatively intact. However, lab dish results frequently do not translate to actual cancer treatment. Clinical trials in humans are needed before any therapeutic claims can be made.
Which cancers responded best to CBD in the lab?
Colon cancer cells (CaCo-2) were most sensitive, requiring only 4.3 micromolar CBD to kill half the cells. Cervical (9.4) and breast cancer (10.3) cells also responded but required higher concentrations.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07174APA
Montes-de-Oca-Saucedo, Carlos R; Perales-Martínez, Jonathan E; Arellano-Barrientos, Juan C; Rodríguez-Tovar, Luis E; Nevárez-Garza, Alicia M; Garza-Arredondo, Aimé J; Saucedo-Cárdenas, Odila; Hernández-Vidal, Gustavo; Soto-Domínguez, Adolfo; Castillo-Velázquez, Uziel. (2025). Targeting Human Cancer Cells with Cannabidiol (CBD): Apoptotic Cytotoxicity in HeLa, MDA-MB-231, and CaCo-2 Lines.. International journal of molecular sciences, 26(24). https://doi.org/10.3390/ijms262412136
MLA
Montes-de-Oca-Saucedo, Carlos R, et al. "Targeting Human Cancer Cells with Cannabidiol (CBD): Apoptotic Cytotoxicity in HeLa, MDA-MB-231, and CaCo-2 Lines.." International journal of molecular sciences, 2025. https://doi.org/10.3390/ijms262412136
RethinkTHC
RethinkTHC Research Database. "Targeting Human Cancer Cells with Cannabidiol (CBD): Apoptot..." RTHC-07174. Retrieved from https://rethinkthc.com/research/montes-de-oca-saucedo-2025-targeting-human-cancer-cells
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.